Its administration attenuated the development of signs and symptoms of colitis, reduced colonic expression of TNF-α, Interleukin (IL)-6, and IFN-γ, and reserved colonic down-regulation of PPAR-γ, PXR, and FXR caused by a TNBS model of induced colitis [24]. The gene discussed is IFNG; the disease is colitis.